1. In Vivo
  2. >>Deal-Making

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

 
• By Michael Goodman

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

IV1804_Mesoblast_ 1063586933_1200.jpg

The world of cell therapy has been eclipsed by the early success of oncology companies specializing in adoptive T-cell therapy or ACT. Other companies focusing on various types of multipotent stem cells have been working in the shadows, with little support from the press or the investment community.

But that might be about to change. Mesoblast Ltd.recently posted positive results in a Phase III trial of MSC-100-IV,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By Jo Shorthouse

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By David Wild

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By Ian Taylor

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.